GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Cash Flow from Investing

Panbela Therapeutics (Panbela Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Panbela Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Panbela Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Panbela Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Panbela Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics Cash Flow from Investing Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -0.66 0.40

Panbela Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Panbela Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Panbela Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Panbela Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panbela Therapeutics  (OTCPK:PBLA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Panbela Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Panbela Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Panbela Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Panbela Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Panbela Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Panbela Therapeutics's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Panbela Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Panbela Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Panbela Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Panbela Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Panbela Therapeutics paid $0.00 Mil for other investing activities.


Panbela Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Panbela Therapeutics (Panbela Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Executives
Jennifer K. Simpson director, officer: President and CEO C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath officer: V.P. of Finance & CFO 4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob director 712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer director 712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust 10 percent owner 1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson 10 percent owner 130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel director 712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill director 712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen officer: Chief Financial Officer 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen director 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr director
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen director 712 VISTA BLVD, #305, WACONIA MN 55387

Panbela Therapeutics (Panbela Therapeutics) Headlines

From GuruFocus

Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023

By Stock market mentor Stock market mentor 01-12-2023

Panbela Announces Pricing of Approximately $15 Million Public Offering

By Stock market mentor Stock market mentor 01-26-2023